Scribd Logo
Upload

Welcome to Scribd!

  • Untitled

    Uploaded by

    Abdul Akhtar
    7 views1 page
    PCSK9 inhibitors are monoclonal antibodies that have been shown to lower LDL cholesterol levels by up to 60% independent of other therapies. They are currently recommended for secondary prevention of cardiovascular events due to their high cost, though trials have demonstrated their ability to reduce cardiovascular events when added to other treatments. PCSK9 inhibitors work by inhibiting the PCSK9 protein in the liver that prevents the removal of LDL cholesterol from the bloodstream.

    Original Description:

    Copyright

    © © All Rights Reserved

    Available Formats

    DOCX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    PCSK9 inhibitors are monoclonal antibodies that have been shown to lower LDL cholesterol levels by up to 60% independent of other therapies. They are currently recommended for secondary prevention of cardiovascular events due to their high cost, though trials have demonstrated their ability to reduce cardiovascular events when added to other treatments. PCSK9 inhibitors work by inhibiting the PCSK9 protein in the liver that prevents the removal of LDL cholesterol from the bloodstream.

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd
    Flag for inappropriate content
    7 views1 page

    Untitled

    Uploaded by

    Abdul Akhtar
    PCSK9 inhibitors are monoclonal antibodies that have been shown to lower LDL cholesterol levels by up to 60% independent of other therapies. They are currently recommended for secondary prevention of cardiovascular events due to their high cost, though trials have demonstrated their ability to reduce cardiovascular events when added to other treatments. PCSK9 inhibitors work by inhibiting the PCSK9 protein in the liver that prevents the removal of LDL cholesterol from the bloodstream.

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd
    Flag for inappropriate content
    of 1

    PCSK 9 inhibitors

    PCSK-9 inhibitors are relatively new monoclonal antibody


    agents and have demonstrated improvement in LDL-C by up
    to 60%, and this effect is thought to be independent of
    additional therapy already initiated. Their use is currently
    recommended in secondary prevention, as they can be
    difficult to access and their high cost prohibitive for most
    patients/health systems.
    The JUPITER trial was one of the first to demonstrate an
    inflammatory component to atherosclerosis, and the
    FOURIER and ODYSSEY trials have since demonstrated a
    reduction in cardiovascular events with the addition of PCSK-
    9 inhibitors.

    You might also like